A low cost experimental vaccine protects pigs against circovirus

Researchers from CReSA (Dr Fernando Rodriguez and Dr Joaquim Segalés) have published an article in the Vaccine journal demonstrating the capability of Trichoplusia ni insect larvae to produce the recombinant capsid protein (Cap) of porcine circovirus type 2 (PCV2) and the potential use of this protein to obtain a low cost experimental vaccine against this virus.

Porcine circovirosis is a multifactorial disease that causes significant economic losses. Currently, there are available commercial PCV2 vaccines, some of them also based on the baculovirus-derived recombinant Cap protein, but in these cases they are produced in cell-based bioreactors. One of the drawbacks of such vaccines is the high production cost.

The originality of the new vacine resides in using as biofactories one of the natural hosts for baculovirus: the Trichoplusia ni insect larvae, allowing for a much more competitive production cost.

This work was possible thanks to the support of National and European funding institutions and the close collaboration between public and private research institutions (CReSA, IRTA, UAB, INIA) and ALGENEX (owner company of the methodology of protein expression in Tricholupsia ni larvae).

To contact to researchers:

Dr. Fernando Rodríguez González
e-mail: fernando.rodriguez@cresa.uab.cat 
Phone: +34 93 581 45 62

Dr. Joaquim Segalés Coma
e-mail: joaquim.segales@cresa.uab.cat 
Phone: +34 93 581 45 63

Download the full article: Click Here

To learn more about ALGENEX: www.algenex.es  

¡Recommend this page!: